The authors found that sLeA-targeted CAR-T cells produce TNF-related apoptosis-inducing ligand (TRAIL) upon engaging sLeA+ tumor cells, and eliminated sLeA− tumor cells previously exposed to systemic or local LDRT in a TRAIL-dependent manner (161).These results suggest a synergistic therapeutic effect of LDRT in combination with CAR-T cell therapy in solid tumors, which merits prospective evaluation in a Phase I/II trial. The gene discussed is TNFSF10; the disease is neoplasm.